JP2007519646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519646A5 JP2007519646A5 JP2006549961A JP2006549961A JP2007519646A5 JP 2007519646 A5 JP2007519646 A5 JP 2007519646A5 JP 2006549961 A JP2006549961 A JP 2006549961A JP 2006549961 A JP2006549961 A JP 2006549961A JP 2007519646 A5 JP2007519646 A5 JP 2007519646A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- formula
- weight loss
- skf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 208000016261 weight loss Diseases 0.000 claims 8
- 230000004580 weight loss Effects 0.000 claims 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- -1 GMC- 1111 Chemical compound 0.000 claims 3
- 229940086609 Lipase inhibitor Drugs 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 239000002830 appetite depressant Substances 0.000 claims 3
- 229960003638 dopamine Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229940127230 sympathomimetic drug Drugs 0.000 claims 2
- GELJVTSEGKGLDF-QDSMGTAFSA-N (2s)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C([C@H]1COC=2C=CC3=C(C=2O1)CC(N3)=O)NCC1=CC=CC=C1 GELJVTSEGKGLDF-QDSMGTAFSA-N 0.000 claims 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 1
- DVLKVIJLALMCBQ-VENMBWNLSA-N (3R,4aR,10aS)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline hydrochloride Chemical compound Cl.C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O DVLKVIJLALMCBQ-VENMBWNLSA-N 0.000 claims 1
- MNIXOHSBCFNRSH-UQGUCNKVSA-N (6ar,9r,10ar)-7-methyl-9-(1,2,4-triazol-1-ylmethyl)-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)N1C=NC=N1 MNIXOHSBCFNRSH-UQGUCNKVSA-N 0.000 claims 1
- BGOQGUHWXBGXJW-YOEHRIQHSA-N (6as,12br)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol Chemical compound N1CC2=CC=CC=C2[C@@H]2[C@@H]1CCC1=C2C=C(O)C(O)=C1 BGOQGUHWXBGXJW-YOEHRIQHSA-N 0.000 claims 1
- SNPPWIUOZRMYNY-SECBINFHSA-N (R)-bupropion Chemical compound CC(C)(C)N[C@H](C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-SECBINFHSA-N 0.000 claims 1
- JUDKOGFHZYMDMF-UHFFFAOYSA-N 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Chemical compound C1=2C=C(O)C(O)=CC=2CCNCC1C1=CC=CC=C1 JUDKOGFHZYMDMF-UHFFFAOYSA-N 0.000 claims 1
- JTYVLKBMXTUORS-UHFFFAOYSA-N 6-(dipropylamino)-3,4,5,6,7,8-hexahydro-2h-naphthalen-1-one Chemical compound C1C(N(CCC)CCC)CCC2=C1CCCC2=O JTYVLKBMXTUORS-UHFFFAOYSA-N 0.000 claims 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 claims 1
- NQRIKTDKFHAOKC-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.C1CN(C)CCN1C1=CC=CC2=C1OC(=O)N2 NQRIKTDKFHAOKC-UHFFFAOYSA-N 0.000 claims 1
- RRLWEQBPSAFVAS-UHFFFAOYSA-N 7-[3-[4-(2,3-dimethylphenyl)piperazin-1-yl]propoxy]-1h-quinolin-2-one Chemical compound CC1=CC=CC(N2CCN(CCCOC=3C=C4NC(=O)C=CC4=CC=3)CC2)=C1C RRLWEQBPSAFVAS-UHFFFAOYSA-N 0.000 claims 1
- XKTGLDSNABUNGD-UHFFFAOYSA-N 9-bromo-5-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol Chemical compound C1NCCC=2C(Br)=C(O)C(O)=CC=2C1C1=CC=CC=C1 XKTGLDSNABUNGD-UHFFFAOYSA-N 0.000 claims 1
- GHWJEDJMOVUXEC-UHFFFAOYSA-N 9-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol Chemical compound C1NCCC=2C(Cl)=C(O)C(O)=CC=2C1C1=CC=CC=C1 GHWJEDJMOVUXEC-UHFFFAOYSA-N 0.000 claims 1
- HJWHHQIVUHOBQN-UHFFFAOYSA-N 9-chloro-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol Chemical compound C1N(CC=C)CCC=2C(Cl)=C(O)C(O)=CC=2C1C1=CC=CC=C1 HJWHHQIVUHOBQN-UHFFFAOYSA-N 0.000 claims 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 201000007114 MHC class I deficiency Diseases 0.000 claims 1
- QBUVZVXIRYFENV-UHFFFAOYSA-N N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol Chemical compound C1=2C=C(O)C(O)=CC=2CCN(CC=C)CC1C1=CC=CC=C1 QBUVZVXIRYFENV-UHFFFAOYSA-N 0.000 claims 1
- FHYWNBUFNGHNCP-UHFFFAOYSA-N N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide Chemical compound Br.C1N(C)CCC(C(=C(O)C(O)=C2)Cl)=C2C1C1=CC=CC(C)=C1 FHYWNBUFNGHNCP-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 claims 1
- HGMLOQOHAYKVJN-UHFFFAOYSA-N [4-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]-2-chlorophenyl]methanol Chemical compound C1=C(Cl)C(CO)=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 HGMLOQOHAYKVJN-UHFFFAOYSA-N 0.000 claims 1
- KTEBZVJGMARTOQ-GCJKJVERSA-N adrogolide Chemical compound CC(=O)OC1=C(OC(C)=O)C=C2[C@H]3C(C=C(S4)CCC)=C4CN[C@@H]3CCC2=C1 KTEBZVJGMARTOQ-GCJKJVERSA-N 0.000 claims 1
- 229950007871 adrogolide Drugs 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- REHAKLRYABHSQJ-KDOFPFPSSA-N chembl28338 Chemical compound OC1=C(O)C=C2[C@H]3C(C=C(S4)CCC)=C4CN[C@@H]3CCC2=C1 REHAKLRYABHSQJ-KDOFPFPSSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- XFBDGHFDKJITGC-JLHYYAGUSA-N gbr-12783 Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN(CC1)CCN1C\C=C\C1=CC=CC=C1 XFBDGHFDKJITGC-JLHYYAGUSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 229960001794 melevodopa Drugs 0.000 claims 1
- WFGNJLMSYIJWII-FJXQXJEOSA-N methyl (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WFGNJLMSYIJWII-FJXQXJEOSA-N 0.000 claims 1
- WEIMMECSAQVSGO-UHFFFAOYSA-N n-(3-hydroxy-4-propylphenyl)acetamide Chemical compound CCCC1=CC=C(NC(C)=O)C=C1O WEIMMECSAQVSGO-UHFFFAOYSA-N 0.000 claims 1
- YYMXEVCLZQHDGV-UHFFFAOYSA-N n-[2-(3,4-dihydroxyphenyl)ethyl]-3-(6-oxo-3h-purin-9-yl)propanamide Chemical compound C1=C(O)C(O)=CC=C1CCNC(=O)CCN1C(NC=NC2=O)=C2N=C1 YYMXEVCLZQHDGV-UHFFFAOYSA-N 0.000 claims 1
- OUUMPVSFLSOGJZ-UHFFFAOYSA-N n-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]pyrimidin-2-amine Chemical compound C1CC(NC=2N=CC=CN=2)CCC1CCN(CC1)CCN1C1=CC=CC=C1 OUUMPVSFLSOGJZ-UHFFFAOYSA-N 0.000 claims 1
- YBCGYAGNYOYLDH-IFXJQAMLSA-N n-[[(6ar,9s)-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-yl]methyl]-n-methylprop-2-yn-1-amine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)CN(CC#C)C)C2)=C3C2=CNC3=C1 YBCGYAGNYOYLDH-IFXJQAMLSA-N 0.000 claims 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 1
- 229960001243 orlistat Drugs 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 229960004558 terguride Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- UCZYAFAFGFTZEW-CYBMUJFWSA-N u 86170f Chemical compound C([C@H](C1)N(CCC)CCC)C2=CC=CC3=C2N1C(=O)N3 UCZYAFAFGFTZEW-CYBMUJFWSA-N 0.000 claims 1
- XTWUNLMHXDDOMD-SNVBAGLBSA-N u91356a Chemical compound C([C@H](C1)NCCC)C2=CC=CC3=C2N1C(=O)N3 XTWUNLMHXDDOMD-SNVBAGLBSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04001282 | 2004-01-22 | ||
| EP04005816 | 2004-03-11 | ||
| PCT/EP2005/000165 WO2005070427A1 (en) | 2004-01-22 | 2005-01-11 | Compounds for the sustained reduction of body weight |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007519646A JP2007519646A (ja) | 2007-07-19 |
| JP2007519646A5 true JP2007519646A5 (enExample) | 2008-02-14 |
Family
ID=34809747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549961A Pending JP2007519646A (ja) | 2004-01-22 | 2005-01-11 | 体重の持続的低減のための化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050203124A1 (enExample) |
| EP (1) | EP1727547A1 (enExample) |
| JP (1) | JP2007519646A (enExample) |
| AU (1) | AU2005205880B2 (enExample) |
| CA (1) | CA2553649A1 (enExample) |
| NZ (1) | NZ547919A (enExample) |
| WO (1) | WO2005070427A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2269608A3 (en) * | 2003-10-16 | 2011-02-16 | NeuroSearch AS | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
| CA2554617A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
| EP1779851A1 (en) | 2005-10-31 | 2007-05-02 | Boehringer Ingelheim Pharma GmbH & Co.KG | Treatment of diabetes |
| EP2222303A1 (en) * | 2007-11-20 | 2010-09-01 | NeuroSearch A/S | A method for treating addiction |
| US20110118304A1 (en) * | 2007-11-20 | 2011-05-19 | Neurosearch A/S | Method for treating over-eating disorders |
| EP2237781A2 (en) * | 2007-12-20 | 2010-10-13 | NeuroSearch A/S | Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity |
| WO2009080693A2 (en) * | 2007-12-20 | 2009-07-02 | Neurosearch A/S | Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker |
| EP2814473B1 (en) | 2012-02-16 | 2018-10-10 | Saniona A/S | Pharmaceutical compositions for combination therapy |
| US9579288B2 (en) | 2015-03-03 | 2017-02-28 | Saniona A/S | Tesofensine and beta blocker combination formulations |
| WO2020084065A1 (en) * | 2018-10-24 | 2020-04-30 | Saniona A/S | Transdermal tropane compositions and methods for using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993009814A1 (en) * | 1991-11-15 | 1993-05-27 | Research Triangle Institute | Cocaine receptor binding ligands |
| DK154192D0 (da) * | 1992-12-23 | 1992-12-23 | Neurosearch As | Heterocycliske forbindelser |
| US5554626A (en) * | 1992-12-23 | 1996-09-10 | Neurosearch A/S | Substituted heterocyclic compounds as dopamine-reuptake inhibitors |
| EE03877B1 (et) * | 1994-04-19 | 2002-10-15 | Neurosearch A/S | Tropaan-2-aldoksiimi derivaadid neurotransmitteritagasihaarde inhibiitoritena |
| SK281813B6 (sk) * | 1996-02-22 | 2001-08-06 | Neurosearch A/S | Tropánové deriváty, spôsob ich prípravy, použitie a farmaceutická kompozícia s ich obsahom |
| US6262081B1 (en) * | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
| WO2002102801A1 (en) * | 2001-05-23 | 2002-12-27 | Neurosearch A/S | Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| DE10148233A1 (de) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme |
| WO2004072075A1 (en) * | 2003-02-12 | 2004-08-26 | Neurosearch A/S | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| EP2269608A3 (en) * | 2003-10-16 | 2011-02-16 | NeuroSearch AS | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
| CA2554617A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
| JP2008501656A (ja) * | 2004-06-04 | 2008-01-24 | ノイロサーチ アクティーゼルスカブ | β−アミロイド（Ａβ４０及びＡβ４２）生成阻害のためのモノアミン神経伝達物質再取り込み阻害剤 |
-
2005
- 2005-01-11 CA CA002553649A patent/CA2553649A1/en not_active Abandoned
- 2005-01-11 NZ NZ547919A patent/NZ547919A/en not_active IP Right Cessation
- 2005-01-11 EP EP05700803A patent/EP1727547A1/en not_active Withdrawn
- 2005-01-11 WO PCT/EP2005/000165 patent/WO2005070427A1/en not_active Ceased
- 2005-01-11 JP JP2006549961A patent/JP2007519646A/ja active Pending
- 2005-01-11 AU AU2005205880A patent/AU2005205880B2/en not_active Ceased
- 2005-01-21 US US11/039,991 patent/US20050203124A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230301922A1 (en) | Layered Pharmaceutical Formulations | |
| JP6117845B2 (ja) | ニタゾキサニドの制御放出医薬配合物 | |
| US5552429A (en) | Potentiation of drug response | |
| US20080051443A1 (en) | Compounds for the reduction of excessive food intake | |
| JP2006143751A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2008524332A (ja) | 睡眠傷害のための医薬組成物 | |
| JP2004526788A5 (enExample) | ||
| JP2012520883A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2006526590A5 (enExample) | ||
| JP2007519646A5 (enExample) | ||
| EP1077704A1 (en) | Combination therapy for treatment of depression | |
| JP2008543936A5 (enExample) | ||
| JP2007519646A (ja) | 体重の持続的低減のための化合物 | |
| JP2009506043A5 (enExample) | ||
| CA2519584A1 (en) | Pramipexole for reducing excessive food intake by children | |
| US20040266794A1 (en) | Pramipexole for the reduction of excessive food intake for children | |
| US20050228052A1 (en) | Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine | |
| JP2002523362A5 (enExample) | ||
| EP1940404A2 (en) | Pharmaceutical composition comprising 2,3-disubstituted tropanes for the treatment of disorders of sexual desire | |
| AR068792A1 (es) | Composiciones agonistas de dopamina de liberacion controlada y metodo de tratamiento |